AI Article Synopsis

  • Delayed surgeries significantly increase the risk of disease progression and negative outcomes in lung cancer patients, particularly those with Non-Small Cell Lung Cancer (NSCLC).
  • The study analyzed data from 3,088 NSCLC patients, revealing that over 40% experienced delays in surgical treatment due to geographic variability and various risk factors.
  • Key factors contributing to these delays included advanced cancer stages, treatment at specific regional hospitals, existing health conditions, and diagnoses made during the COVID-19 pandemic.

Article Abstract

Objectives: Delayed surgery is significantly associated with an increased risk of disease progression and adverse outcomes in lung cancer. Evidence is available on the variation in delayed surgical treatment among patients with Non-Small Cell Lung Cancer (NSCLC). However, the relative contribution of patient- and area-level risk factors to the geographic patterns of delayed surgery in patients with NSCLC is poorly understood. Therefore, we aimed to explore the geographic variation in delay to surgical treatment among patients with NSCLC.

Materials And Methods: This study utilized data from the Victorian Lung Cancer Registry (VLCR) and the Australian Bureau of Statistics (ABS). A total of 3,088 patients with NSCLC who had undergone surgery were included. We applied a Bayesian spatial multilevel model incorporating spatially structured and unstructured random effects to examine patient and area-level risk factors associated with delays to surgical treatment. Model comparison was conducted using the Deviance Information Criterion (DIC).

Results: Over one-third (40.45 %) of NSCLC patients experienced delayed surgical treatment. Significant geographic variation in delayed surgical treatment among NSCLC patients across Local Government Areas (LGAs) was observed. Factors significantly associated with higher odds of delayed surgical treatment included clinical stage II (AOR = 1.56, 95 % CrI: 1.26-1.92), stage III (AOR = 1.90, 95 % CrI: 1.46-2.47), stage IV (AOR = 2.04, 95 % CrI: 1.15-3.61), treatment at inner regional hospitals (AOR = 2.86, 95 % CrI: 2.17-3.70), presence of comorbidities (AOR = 1.19, 95 % CrI: 1.02-1.40), and diagnosis during the COVID-19 pandemic (AOR = 1.32, 95 % CrI: 1.10-1.57).

Conclusions: This study highlights the need to improve the treatment pathway for patients with NSCLC by reducing the time between diagnosis and surgery. Future targeted initiatives are essential to promote timely surgeries for NSCLC patients, especially in high-need areas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2024.108077DOI Listing

Publication Analysis

Top Keywords

surgical treatment
28
95 % cri
24
lung cancer
16
delayed surgical
16
geographic variation
12
patients nsclc
12
nsclc patients
12
treatment
9
patients
9
variation delay
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!